vTv Therapeutics Inc (VTVT): VTVT completes enrollment in first part...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	826
Posts	119569
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: None

Wednesday, 09/07/2016 11:13:25 AM

Wednesday, September 07, 2016 11:13:25 AM

VTVT completes enrollment in first part of phase-3 AD trial:

http://finance.yahoo.com/news/vtv-therapeutics-completes-enrollment-part-110000201.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent VTVT News

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT • PR Newswire (US) • 03/19/2024 12:30:00 PM
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:47:37 PM
Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/06/2024 12:52:29 AM
Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 01:04:31 PM
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference • GlobeNewswire Inc. • 03/01/2024 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:26:55 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 02:14:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:08:30 PM
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE • PR Newswire (US) • 02/22/2024 09:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:26:26 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:28:15 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:21:45 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:23:40 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:22:56 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:19:26 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:31 PM
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/09/2023 09:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:16 PM
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 01:00:00 PM
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 11/02/2023 12:00:54 PM

More VTVT News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover